Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C142826
http://purl.obolibrary.org/obo/NCIT_C142826
|
|---|---|
| Preferred Name | Monoclonal Antibody TRK-950 |
| Definitions |
A proprietary monoclonal antibody targeting an as of yet undisclosed tumor-associated antigen (TAA), with potential antineoplastic activity. Although the mechanism of action has not been elucidated presumably monoclonal antibody TRK-950 binds to a specific TAA on the cell surface of tumor cells and may induce complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This may lead to the death of tumor cells expressing the TAA.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A proprietary monoclonal antibody targeting an as of yet undisclosed tumor-associated antigen (TAA), with potential antineoplastic activity. Although the mechanism of action has not been elucidated presumably monoclonal antibody TRK-950 binds to a specific TAA on the cell surface of tumor cells and may induce complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This may lead to the death of tumor cells expressing the TAA. |
|---|---|
| prefLabel | Monoclonal Antibody TRK-950
|
| label | Monoclonal Antibody TRK-950
|
| NCI_META_CUI | CL540696
|
| PDQ_Closed_Trial_Search_ID | 791700
|
| code | C142826
|
| prefixIRI | NCIT:C142826
|
| in_subset |
See more
See less
|
| Display_Name | Monoclonal Antibody TRK-950
|
| Preferred_Name | Monoclonal Antibody TRK-950
|
| FDA_UNII_Code | L1R0M8P1GD
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Monoclonal Antibody TRK-950
|
| NCI_Drug_Dictionary_ID | 791700
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 791700
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |